Annalise Enterprise CXR

by Annalise.ai

🟢Active

An AI-assisted chest X-ray decision-support system from Annalise.ai. It analyzes adult chest radiographs for numerous radiological findings and provides clinicians with secondary review and worklist-prioritization support.

HealthcareFounded by Dimitry Tran, Aengus TranVisit website →
🔍 Last checked: 8/29/2026 · Confidence: 90%

Why Abandoned

Annalise.ai continues to maintain an official product page for Enterprise CXR and lists current regulatory and product information. No verified shutdown or acquisition of the product was found.

🩺 Health Signals

3d ago
HTTP Status
403
Response
SSL
Confidence
90%
Domain expires
Last content change
Last tweet
API status

📅 Timeline

2020-07-06

Annalise CXR launched in Australia

Annalise.ai announced the Australian launch of its chest X-ray AI decision-support product, developed with radiology provider I-MED Radiology Network.

2021-06-30

Series B funding announced

Annalise.ai announced an AU$129 million Series B round led by Skip Capital and Main Sequence Ventures to support international expansion and product development.

2022-03-29

FDA clearance announced

Annalise.ai announced U.S. FDA 510(k) clearance for Annalise CXR as a triage and notification device covering specified chest X-ray findings.

2022-10-20

Expanded FDA clearance announced

The company announced an additional FDA clearance broadening Annalise CXR's U.S. indications to eight findings on chest X-rays.

🔄 Alternatives to Annalise Enterprise CXR

🪦 Other dead Healthcare tools

Frequently Asked Questions

What is Annalise Enterprise CXR?

Annalise Enterprise CXR is AI-based clinical decision-support software that reviews adult chest X-rays and highlights suspected radiological findings for clinicians.

How does Annalise Enterprise CXR work?

It applies trained medical-imaging models to chest radiographs, then presents suspected findings and related decision-support information within a radiology workflow. Availability of individual features depends on local regulatory clearance.

What can Annalise Enterprise CXR detect?

The global product is designed to identify a broad range of chest X-ray findings. The exact supported findings and intended use vary by country and regulatory authorization, so users should consult local labeling.

Is Annalise Enterprise CXR FDA cleared?

Yes. Annalise.ai has announced U.S. FDA 510(k) clearances for Annalise CXR triage and notification capabilities, including an expanded set of eight findings. FDA-cleared functionality is narrower than some versions marketed elsewhere.

Who uses Annalise Enterprise CXR?

It is intended for healthcare organizations and clinicians interpreting adult chest radiographs, including radiology departments, hospitals, and imaging networks. It supports rather than replaces clinical judgment.